The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group
- PMID: 35264411
- PMCID: PMC9489037
- DOI: 10.1183/16000617.0218-2021
The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group
Abstract
Tuberculosis (TB) is still responsible for the deaths of >1 million people yearly worldwide, and therefore its correct diagnosis is one of the key components of any TB eradication programme. However, current TB diagnostic tests have many limitations, and improved diagnostic accuracy is urgently needed. To improve the diagnostic performance of traditional serology, a combination of different Mycobacterium tuberculosis (MTB) antigens and different antibody isotypes has been suggested, with some showing promising performance for the diagnosis of active TB. Given the incomplete protection conferred by bacille Calmette-Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggesting that they may not be sufficient and warranting the need for other types of immunity. The role of antibodies as tools for TB therapy, TB diagnosis and TB vaccine design is discussed. Finally, we propose that the inclusion of antibody-based TB vaccines in current clinical trials may be advisable to improve protection.
Copyright ©The authors 2022.
Conflict of interest statement
Conflict of interest: S.T. Melkie reports support for the present manuscript: co-funded by the EACEA (Education, Audiovisual and Culture Executive Agency, award 2015–2323) of the European Commission, receives a scholarship from the EACEA. Registered in the EMJMD LIVE (Erasmus+ Mundus Joint Master Degree Leading International Vaccinology Education). Conflict of interest: L. Arias has nothing to disclose. Conflict of interest: C. Farroni has nothing to disclose. Conflict of interest: M. Jankovic Makek reports receiving consulting fees from Insmed incorporated and Biomerieux outside the submitted work. Conflict of interest: D. Goletti has nothing to disclose. Conflict of interest: C. Vilaplana reports support for the present manuscript received from CIBER Enfermedades Respiratorias (CB06/06/0031), payment made to the institution. Grants or contracts received from Spanish Government-FEDER Funds through CPII18/00031, outside the submitted work. Other non-financial interests reported as follows: C. Vilaplana's lab hosts secondments from the EMJMD LIVE MsC students (Erasmus+ Mundus Joint Master Degree Leading International Vaccinology Education), co-funded by the EACEA (Education, Audiovisual and Culture Executive Agency, award 2015–2323).
Figures

Similar articles
-
Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.Semin Immunol. 2018 Oct;39:88-101. doi: 10.1016/j.smim.2018.07.001. Epub 2018 Jul 7. Semin Immunol. 2018. PMID: 30327124 Review.
-
Listeria-Vectored Multiantigenic Tuberculosis Vaccine Enhances Protective Immunity against Aerosol Challenge with Virulent Mycobacterium tuberculosis in BCG-Immunized C57BL/6 and BALB/c Mice.mBio. 2022 Jun 28;13(3):e0068722. doi: 10.1128/mbio.00687-22. Epub 2022 Jun 1. mBio. 2022. PMID: 35642945 Free PMC article.
-
Tuberculosis vaccine: A journey from BCG to present.Life Sci. 2020 Jul 1;252:117594. doi: 10.1016/j.lfs.2020.117594. Epub 2020 Apr 16. Life Sci. 2020. PMID: 32305522 Review.
-
A review of the efficacy of clinical tuberculosis vaccine candidates in mouse models.Front Immunol. 2025 May 29;16:1609136. doi: 10.3389/fimmu.2025.1609136. eCollection 2025. Front Immunol. 2025. PMID: 40510368 Free PMC article. Review.
-
[Recent progress in mycobacteriology].Kekkaku. 2007 Oct;82(10):783-99. Kekkaku. 2007. PMID: 18018602 Japanese.
Cited by
-
MetE: a promising protective antigen for tuberculosis vaccine development.Front Immunol. 2025 Jul 21;16:1593263. doi: 10.3389/fimmu.2025.1593263. eCollection 2025. Front Immunol. 2025. PMID: 40761798 Free PMC article.
-
High Positivity Rate of Urinary Mycobacterium tuberculosis Antigens Cocktail (ESAT-6, CFP-10, and MPT-64) in Active Tuberculosis Patients With and Without Human Immunodeficiency Virus Infection: A Cross-Sectional Study.Clin Pathol. 2023 Sep 13;16:2632010X231198831. doi: 10.1177/2632010X231198831. eCollection 2023 Jan-Dec. Clin Pathol. 2023. PMID: 37719805 Free PMC article.
-
Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches.Diseases. 2024 Sep 3;12(9):202. doi: 10.3390/diseases12090202. Diseases. 2024. PMID: 39329871 Free PMC article. Review.
-
Primary Tuberculosis of Buccal and Labial Mucosa: Literature Review and a Rare Case Report of a Public Health Menace.Case Rep Dent. 2023 Oct 5;2023:6543595. doi: 10.1155/2023/6543595. eCollection 2023. Case Rep Dent. 2023. PMID: 37842328 Free PMC article.
-
Role of B Cells in Mycobacterium Tuberculosis Infection.Vaccines (Basel). 2023 May 6;11(5):955. doi: 10.3390/vaccines11050955. Vaccines (Basel). 2023. PMID: 37243059 Free PMC article. Review.
References
-
- World Health Organization . Global Tuberculosis Report 2021. 2021. www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberc...
-
- Ghiasi M, Pande T, Pai M. Advances in tuberculosis diagnostics. Curr Trop Med Reports 2015; 2: 54–61. doi:10.1007/s40475-015-0043-1 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical